The CD38/NAD/SIRTUIN1/EZH2 Axis Mitigates Cytotoxic CD8 T Cell Function and Identifies Patients with SLE Prone to Infections
Open Access
- 1 January 2020
- journal article
- research article
- Published by Elsevier BV in Cell Reports
- Vol. 30 (1), 112-123.e4
- https://doi.org/10.1016/j.celrep.2019.12.014
Abstract
No abstract availableFunding Information
- National Institutes of Health
- NIH (RO1 AI42269, RO1 AI148161)
This publication has 86 references indexed in Scilit:
- Targeting Sirtuin 1 to Improve Metabolism: All You Need Is NAD+?Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2011
- Integrative genomics viewerNature Biotechnology, 2011
- Measuring dementia carers' unmet need for services - an exploratory mixed method studyBMC Health Services Research, 2010
- The Sequence Alignment/Map format and SAMtoolsBioinformatics, 2009
- Ultrafast and memory-efficient alignment of short DNA sequences to the human genomeGenome Biology, 2009
- Runx3 and T-box proteins cooperate to establish the transcriptional program of effector CTLsThe Journal of Experimental Medicine, 2009
- Model-based Analysis of ChIP-Seq (MACS)Genome Biology, 2008
- Enhancer of Zeste Homologue 2 (EZH2) Down-regulates RUNX3 by Increasing Histone H3 MethylationJournal of Biological Chemistry, 2008
- A Bivalent Chromatin Structure Marks Key Developmental Genes in Embryonic Stem CellsCell, 2006
- Derivation of the sledai. A disease activity index for lupus patientsArthritis & Rheumatism, 1992